Articles: function.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The current GOLD strategy recommends combining two long-acting bronchodilators for the maintenance treatment of patients with moderate-to-severe COPD. The SHINE study evaluated the effect of QVA149, a dual bronchodilator combining the LABA indacaterol and the LAMA glycopyrronium (NVA237), compared with glycopyrronium, indacaterol, tiotropium monotherapies and placebo. ⋯ Kenneth Chapman: Consultant fee, speaker bureau, advisory committee, etc.: "KRC holds the GSK-CIHR Research Chair in Respiratory Healthcare Delivery at the University Health Network, has served as a consultant to CSL Behring, GlaxoSmithKline, Novartis, Nycomed (Takeda), and Talecris (Grifols), and has received payment for lectures or service on speakers bureaus from Boehringer-Ingelheim, GlaxoSmithKline, Grifols, Nycomed (Takeda), Family Physicians Airways Group of Canada, Canadian Network for Respiratory Care, and Talecris. " Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Nicola Gallagher: Employee: Novartis employee Huilin Hu: Employee: Novartis employee Donald Banerji: Employee: Novartis employeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
COPD Rehabilitation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Acute exacerbation is a common cause of hospital admission in patients with chronic obstructive pulmonary disease (COPD). COPD also involves non-pulmonary manifestations including exercise intolerance and skeletal muscle dysfunction. These manifestations added to the hospitalization stay have been associated to a loss of muscle mass partially recovered 3 months after discharge. The aims of this study were to examine the effects of a physical therapy (PT) program in hospitalized patients due to an acute exacerbation of COPD (AE-COPD). ⋯ The following authors have nothing to disclose: Irene Torres-Sánchez, Marie Carmen Valenza, Gerald Valenza-Demet, Irene Cabrera-Martos, María José Flores-Barba, Sonia Rodríguez-MoralesNo Product/Research Disclosure Information.
-
Symptoms of Respiratory Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Studies of military personnel deployed to Operations Iraqi Freedom and Enduring Freedom have suggested an increase in chronic lung disease due to environmental exposures. Findings are based primarily on increased respiratory symptoms and retrospective data. Our previous study (STAMPEDE I) did not identify any acute interstitial or inflammatory process. The study objective was to complete a comprehensive evaluation of active duty military with deployment-related pulmonary symptoms and identify etiology of symptoms. ⋯ Michael Morris: Consultant fee, speaker bureau, advisory committee, etc.: Speaker Bureau for Spiriva with Pfizer/Boehringer/Ingelheim The following authors have nothing to disclose: Andrew Skabelund, Georgette Haislip, Pedro LuceroNo Product/Research Disclosure Information.
-
Pediatric Pulmonary Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Neonatal listeriosis, although rare, as incidence, leads to high mortality or outcome with sequelae among survivors. ⋯ Congenital listeriosis is an infection that may lead to severe injuries of almost all organs and may have a poor outcome despite early, proper treatment.Reference #1: Taege AJ. Listeriosis: recognizing it, treating it, preventing it. Cleve Clin J Med. Jun 1999;66(6):375-80DISCLOSURE: The following authors have nothing to disclose: Marta Simon, Manuela Cucerea, Zsuzsanna Gall, Monika Rusneac, Laura Suciu, Raluca Marian, Carmen MovileanuNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Evaluate the impact of lung disease(COPD) chronic obstructive in the quality of life of these patients in the province of Albacete. ⋯ The following authors have nothing to disclose: José Luis Castro Navarro, Miguel Angel Palomino Medina, Pedro J. Tárraga López, Juan Solera Albero, Angel Celada Rodríguez, Enrique Arjona LabordaNo Product/Research Disclosure Information.